<code id='C325370C07'></code><style id='C325370C07'></style>
    • <acronym id='C325370C07'></acronym>
      <center id='C325370C07'><center id='C325370C07'><tfoot id='C325370C07'></tfoot></center><abbr id='C325370C07'><dir id='C325370C07'><tfoot id='C325370C07'></tfoot><noframes id='C325370C07'>

    • <optgroup id='C325370C07'><strike id='C325370C07'><sup id='C325370C07'></sup></strike><code id='C325370C07'></code></optgroup>
        1. <b id='C325370C07'><label id='C325370C07'><select id='C325370C07'><dt id='C325370C07'><span id='C325370C07'></span></dt></select></label></b><u id='C325370C07'></u>
          <i id='C325370C07'><strike id='C325370C07'><tt id='C325370C07'><pre id='C325370C07'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:fashion    - browse:97736
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          hotspot